Navigation Links
Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
Date:6/22/2013

mmercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that novel basal insulin LY2605541 will receive required regulatory approvals or prove to be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

[1] Rosenstock J, Bergenstal RM, Blevins T, Morrow L, Qu Y, Jacober SJ. Improved glycemic control despite reduction in bolus insulin doses with basal insulin LY2605541 compared with basal insulin glargine in patients with type 1 diabetes. Abstract 915-P. Presented at: American Diabetes Association (ADA) 73rd Scientific Sessions; June 21–25, 2013; Chicago, IL.

[2] Rosenstock J, et al. Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study. Diabetes Care. 2013; 36(3): 522–528.

[3] Centers for Disease Control. National Diabetes Fact Sheet-2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed on: February 22, 2012.

[4] International Diabetes Federation. Diabetes Atlas, 5th Edition: Fact Sheet. 2012.

[5] International Diabetes Federation. Diabetes Atlas, 5th Edition: What is Diabetes? http://www.idf.org/diabetesatlas/5e/what-is-diabetes. Accessed on: February 22, 2012.

Refer to: Tamara Hull, +1-317-651-9116, hull_tamara@lilly.com

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
5. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
8. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
9. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
10. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
11. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica ... a leading online community to help oncologists and other ... available regarding the use of targeted therapies and immunotherapies, ... research and treatment.  Every September, ... way to raise awareness about blood cancers—helping to increase ...
(Date:9/19/2014)... -- Larry J. Merlo , President and CEO of ... the National Press Club in Washington, D.C. ... stop selling tobacco products and its leadership in driving the ... "Dramatic changes in our health care system pose enormous challenges ... said. "CVS Health has a truly unique combination of business ...
(Date:9/19/2014)... Sept. 19, 2014  Alere Inc. (NYSE: ... the following statement today in support of President ... "As the global leader in rapid diagnostics for ... national strategy to address the serious threat of antibiotic ... the Administration on initiatives to promote the development of ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... Ability of Adecatumumab to Prolong Disease Free Survival ... March 23 Micromet, Inc. (Nasdaq: ... novel, proprietary antibodies for the treatment of cancer, ... of a randomized, controlled phase 2 trial of ...
... announced today that,the fourth LNA-based drug has been ... with cancer have now been treated with the ... Pharma and Enzon,Pharmaceuticals. The U.S. Food and Drug ... (IND) application,for the use of the LNA-based Survivin ...
Cached Medicine Technology:Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 2Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 3Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 4Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 5Another LNA-based RNA Inhibitor Enters Clinical Trials 2Another LNA-based RNA Inhibitor Enters Clinical Trials 3
(Date:9/19/2014)... Hastings and Hastings, a discount accident lawyer in Phoenix, Arizona, ... number of visitors to its new Phoenix personal injury website. ... as well as auto accident cases and slip & fall ... others. Having served the state of Arizona for over 30 ... when it comes to dedicated and focused personal injury legal ...
(Date:9/19/2014)... 2014 Boston Scientific Corp. has moved ... http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled to go to ... LLP reports. According to a Motion filed ... asserts that claims involving its Solyx pelvic mesh device ... Code, a section of which shields manufacturers from ...
(Date:9/19/2014)... 2014 (HealthDay News) -- Although there is mounting ... most middle-aged and older adults in the United ... according to new research. Less than one-quarter ... set by the Department of Health and Human ... essential for promoting health and fitness and staying ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Lipitor lawsuits ... caused some patients to develop Type 2 diabetes continue ... underway in U.S. District Court, District of South Carolina, ... issued on September 12, 2014, discovery is underway and ... report noted that Pfizer, Inc., the manufacturer of Lipitor, ...
(Date:9/19/2014)... In partnership with Raw Beauty NYC, OC healthcare ... project’s social media efforts. StudioPMG is honored to be a ... of beauty as it applies to disabled women. , ... Baer and Vanessa Silberman, who wanted to create a photo ... Dixon, Wendy Crawford, Susan Solman and Sabrina Cohen later joined ...
Breaking Medicine News(10 mins):Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2
... ... Wins ,Wharton Business Plan Competition Michelson Grand Prize with ,Device that Helps Osteoporosis ... for Co-eds, , ... Philadelphia, PA (PRWEB) April 29, 2010 -- The Wharton School of ...
... new gene expression study in embryonic stem cells has uncovered ... than once thought but is also heavily regulated by the ... in the April 30th edition of Cell , a ... the transcription process that serves to regulate expression of as ...
... ... ... version of Greenpeace’s Cool IT Leaderboard (1) reveals how some global IT companies are leading ... energy use, while others seem unable to decide if IT climate solutions are a significant ...
... mutation impacts how the brain communicates with limbs, researcher says ... that causes a phenomenon known as mirror movements has been ... unable to move one side of their body without moving ... right hand, the same movement occurs unintentionally in the left ...
... ... , ... NJ (Vocus) -- Volkmann, a market leader in vacuum conveying, introduces its “No-Tip ... flow issues involved when transferring powders, granules, pellets, capsules, tablets and other bulk ...
... Mice, frogs, and E. coli are standard organisms ... in part to technical advances, the reduced costs of genome ... of organisms used for research has greatly expanded. Scientists ... might better address their specific research question. Eighteen diverse ...
Cached Medicine News:Health News:Wharton Business Plan Competition Michelson Grand Prize Winners Announced 2Health News:Wharton Business Plan Competition Michelson Grand Prize Winners Announced 3Health News:Embryonic stem cells reveal oncogene's secret growth formula 2Health News:IT Leaderboard Showcases Growing Divide Between Talk and Action on Developing Climate Solutions 2Health News:IT Leaderboard Showcases Growing Divide Between Talk and Action on Developing Climate Solutions 3Health News:IT Leaderboard Showcases Growing Divide Between Talk and Action on Developing Climate Solutions 4Health News:Scientists Find Cause of Involuntary Mirror Movements 2
... The Laserex Ultra Q is the fundamental ... cavity optimizes energy delivery and provides 2855% less ... to 2.54.0 mJs in contemporary systems. This ... dramatically reduces the risk of IOL pitting. ...
... The Ultrasonix 500 is a high-end, mobile ... based architecture provides a tremendous amount of ... contrast and resolution. Ultrasonix imaging systems ... modes including B, B/M, Pulsed Doppler, Color ...
Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see....
Protects the eye during or after surgery or trauma. 8mm diameter, lint free keeps cornea moist. Protects retina from operating microscope light rays....
Medicine Products: